Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3Phase 2 2

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 4Genitourinary 4Gastrointestinal 4Gynecologic 2Breast 2CNS 1

Conditions

Sarcoma, Endometrial Stromal 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × trebananib × Gynecologic × Clear all
NCT00479817 2019-12-18

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer

Amgen

Phase 2 Completed
161 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01210222 2018-02-23

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

GOG Foundation

Phase 2 Completed
35 enrolled 9 charts
GynecologicSarcoma

Sarcoma, Endometrial Stromal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡